


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Plaetinck et al.
Serial No : Not assigned
Filed : Herewith (January 25, 2002)
For : CHARACTERISATION OF GENE FUNCTION USING DOUBLE
STRANDED RNA INHIBITION
Examiner : Not assigned
Art Unit : Not assigned



Box PATENT APPLICATION
Commissioner for Patents
Washington, D.C. 20231

**STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98**

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

[X] This Information Disclosure Statement has been filed within three months of the filing date of a National Application.

No fee or certification is required.

PART II - Information Cited

[X] The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

[] The Applicant hereby makes the following additional information of record in the above-identified application:

PART III: Explanation of Non-English Language References and Remarks Concerning Other Information Cited

The following is a concise explanation of the relevance of each non-English language reference listed on the attached form PTO-1449 (modified):

The following are remarks concerning the other information cited:

PART IV: Remarks

A copy of each of the above-identified information is enclosed unless otherwise indicated on the attached form PTO-1449 (modified). It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,

By: 
John R. Van Amsterdam, Reg No. 40,212
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, MA 02210
Telephone (617) 720-3500

Docket No. D0590/7011
Dated: January 25, 2002
xNDD

FORM PTO-1449/A and B (Modified)				APPLICATION NO.: Not assigned		ATTY. DOCKET NO.: D0590/7011	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: Herewith (01-08-02)			
				APPLICANT: Plaetinc et al.			
Sheet 1 of 1				GROUP ART UNIT: Unknown		EXAMINER: Unknown	

Jceas U.S. P.O.
 10/05/108
 01/25/02

U.S. PATENT DOCUMENTS

Examiner's Initials#	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYY
		Number	Kind Code		

FOREIGN PATENT DOCUMENTS

Examiner's Initials#	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
	B1*	CA	2 088 379	A1	Candido et al.	07-30-1994	
	B2*	WO	90/14090		Hem Research, Inc.	11-29-1990	
	B3*	WO	91/15111		Pres. and Fellows of Harvard College	10-17-1991	
	B4*	EP	0 616 035	A2	Max-Planck-Gesellschaft	09-21-1994	
	B5*	WO	95/34680		Trustees of Columbia U. in City of NY	12-21-1995	
	B6*	WO	96/38553		Mouritsen & Elsner A/S	12-05-1996	
	B7*	WO	96/38555		Bogaert et al.	12-05-1996	
	B8*	WO	99/32619		Carnegie Inst. of Wash.; Univ. of Mass.	07-01-1991	
	B9*	WO	99/53050		Commonwealth Sci. and Ind. Res. Org.	10-21-1999	
	B10*	WO	99/61631		Novartis-Erfind. Verwaltung. MBH	12-02-1999	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials#	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C1*	VENNEMA et al., <i>Gene</i> 108(2):201-209 (1991)	
	C2*	GAST, F., <i>Nucleic Acids Res.</i> 17(23):10109 (1989)	
	C3*	FIRE et al., <i>Nature</i> 391:806-811 (1998)	
	C4*	BOGAERT et al., Database Geneseq Acc. No. T71322 (1997) & abstract WO96 38555 (1996)	
	C5*	CHIEN et al., <i>Proc Natl Acad Sci USA</i> 88:9578-9582 (1991)	
	C6*	JAMES et al., Database Medline Acc. No. 97132579	
	C7*	JAMES et al., Database EMBL Acc. No. U70025 (1996)	
	C8*	TIMMONS AND FIRE, <i>Nature</i> 395:854 (1998)	

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/347,311, filed July 2, 1999, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

EXAMINER	DATE CONSIDERED
----------	-----------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.